Current Report Filing (8-k)
April 27 2023 - 9:18AM
Edgar (US Regulatory)
0001695357
false
--12-31
0001695357
2023-04-27
2023-04-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): April 27, 2023
Provention
Bio, Inc.
(Exact
Name of Registrant as Specified in Charter)
| Delaware |
|
001-38552 |
|
81-5245912 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
55
Broad Street, 2nd
Floor
Red
Bank, NJ |
|
07701 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (908) 336-0360
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
stock, $0.0001 par value per share |
|
PRVB |
|
The
Nasdaq Global Select Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
INTRODUCTORY
NOTE
As
previously disclosed in the Current Report on Form 8-K filed on March 13, 2023 with the Securities and Exchange Commission (the “SEC”)
by Provention Bio, Inc., a Delaware corporation (the “Company”), on March 12, 2023, the Company entered into an Agreement
and Plan of Merger (the “Merger Agreement”), with Sanofi S.A., a French société anonyme (“Parent”),
and Parent’s indirect wholly-owned subsidiary, Zest Acquisition Sub, Inc., a Delaware corporation (“Purchaser”). Pursuant
to the Merger Agreement, and upon the terms and subject to the conditions thereof, on March 24, 2023, Purchaser commenced a tender offer
(the “Offer”) to purchase all of the issued and outstanding shares (the “Shares”) of common stock, par value
$0.0001 per share, of the Company at a price of $25.00 per Share, to the seller in cash, without interest, but subject to any applicable
withholding of taxes (the “Offer Price”) upon the terms and subject to the conditions set forth in the Offer to Purchase,
dated March 24, 2023, and in the related Letter of Transmittal.
The
Offer, as extended, expired one minute after 11:59 p.m. Eastern Time, on April 26, 2023 (the “Expiration Time”). The depositary
for the Offer advised that, as of the Expiration Time, a total of 74,490,556 Shares were validly tendered and “received”
(as defined in Section 251(h) of the General Corporation Law of the State of Delaware (the “DGCL”)) by the depository and
not validly withdrawn pursuant to the Offer, representing approximately 73.065% of outstanding Shares as of such time. Accordingly,
the Minimum Tender Condition (as defined in the Merger Agreement) has been satisfied. Each condition to the Offer having been satisfied
or waived, Purchaser irrevocably accepted for payment all Shares that were validly tendered and not validly withdrawn on April 27, 2023.
Parent and Purchaser are required to make prompt payment for such Shares.
On
April 27, 2023, following consummation of the Offer, Purchaser merged with and into the Company (the “Merger”), with the
Company as the surviving corporation. The Merger was completed pursuant to Sections 251(c) and 251(h) of the DGCL.
| Item
1.02 | Termination
of a Material Definitive Agreement. |
In
connection with the closing of the Merger, on April 27, 2023, the Company fully prepaid all loans outstanding pursuant to the
Loan and Security Agreement, dated as of August 31, 2022 (as amended by that certain First Amendment to Loan and Security Agreement,
dated as of February 2, 2023, the “Loan Agreement”), by and among the Company, certain financial institutions party thereto
and Hercules Capital, Inc. and terminated the Loan Agreement.
| Item
2.01 | Completion
of Acquisition or Disposition of Assets. |
At
the effective time of the Merger (the “Effective Time”), each issued and outstanding Share (other than (i) Shares held in
the treasury of the Company or owned by the Company or any direct or indirect wholly owned subsidiary of the Company immediately prior
to the Effective Time, (ii) Shares owned by Parent or any direct or indirect wholly owned subsidiary of Parent (other than Purchaser)
immediately prior to the Effective Time, (iii) Shares irrevocably accepted for purchase in the Offer and (iv) Shares outstanding immediately
prior to the Effective Time and held by stockholders who are entitled to demand, and properly demanded, appraisal for such Shares in
accordance with Section 262 of the DGCL) was cancelled and converted into the right to receive an amount in cash equal to the Offer Price,
without interest, less applicable withholding of taxes.
In
addition, at the Effective Time, each option to purchase Shares granted under the Company’s 2017 Equity Incentive Plan (as amended
and restated) (the “2017 Plan”) and the Company’s 2020 Inducement Plan (as amended) (each such option, a “Company
Stock Option”) that was outstanding and vested immediately prior to the Effective Time, was cancelled, and, in exchange therefor,
the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock
Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of Shares
subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price
over the applicable exercise price per Share under such Company Stock Option.
Further,
each Company Stock Option that was outstanding and unvested immediately prior to the Effective Time, whether or not then subject to any
performance or other vesting condition, vested in full immediately prior to the Effective Time, with any performance condition deemed
achieved in full, and as of the Effective Time, each such Company Stock Option was cancelled, and, in exchange therefor, the holder of
such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an
amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of Shares subject
to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the
applicable exercise price per Share under such Company Stock Option.
Also
at the Effective Time, each (i) warrant to purchase Shares issued by the Company to MDB and certain of MDB’s designees on July
3, 2018 (the “IPO Warrants”) and (ii) warrant to purchase Shares issued by the Company pursuant to those certain Warrant
Agreements, dated as of September 15, 2022 and February 2, 2023, by and between the Company and Hercules Capital, Inc. (the “Term
Loan Warrants,” and together with the IPO Warrants, the “Company Warrants”) that was outstanding immediately prior
to the Effective Time was, with respect to the Term Loan Warrants, cancelled, and, with respect to the IPO Warrants, deemed exercised,
and, in exchange therefor, the holder of such former Company Warrant became entitled to receive (without interest), an amount of cash
equal to the product of (x) the total number of Shares into which the Company Warrant was exercisable as of immediately prior to the
Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company
Warrant.
The
foregoing summary of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to,
and qualified in its entirety by, the full text of the Merger Agreement attached as Exhibit 2.1 to the Current Report on Form 8-K filed
with the SEC by the Company on March 13, 2023 and incorporated herein by reference.
| Item
3.01 | Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
In
connection with the consummation of the Merger, on April 26, 2023, the Company (i) notified The Nasdaq Stock Market LLC (“Nasdaq”)
of the consummation of the Merger and (ii) requested that Nasdaq (x) halt trading of the Shares effective as of the evening of April
26, 2023 after market close and suspend trading in the Shares prior to market open on the morning of April 27, 2023, and (y) file with
the SEC a Notification of Removal from Listing and/or Registration on Form 25 to effect the delisting of all Shares from Nasdaq and the
deregistration of such Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
The Company intends to file with the SEC a Certification and Notice of Termination of Registration on Form 15 under the Exchange Act,
requesting that the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act be suspended.
| Item
3.03 | Material
Modification to Rights of Security Holders. |
The
information contained in the Introductory Note and in Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated
by reference into this Item 3.03.
At
the Effective Time, holders of Shares immediately prior to such time ceased to have any rights as stockholders of the Company (other
than their right to receive the Offer Price for each Share held, pursuant to the Merger Agreement).
| Item
5.01 | Changes
in Control of Registrant. |
At
the Effective Time, the Company became a wholly-owned subsidiary of Parent.
The
information contained in the Introductory Note and in Items 2.01, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated by
reference into this Item 5.01.
| Item
5.02 | Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. |
Directors
In
accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (Ashleigh Palmer; Avery Catlin; Rita
Jain; John Jenkins; Wayne Pisano; and Nancy Wysenski) resigned from his or her respective position as a member of the Company’s
board of directors, and any committee thereof. These resignations were in connection with the Merger and not as a result of any disagreements
between the Company and the resigning individuals on any matters related to the Company’s operations, policies or practices.
As
of the Effective Time, in accordance with the Merger Agreement, Michael Tolpa, the sole director of Purchaser immediately prior to the
Effective Time, became the sole director of the Company as the surviving corporation. After the Effective Time, Aventis, Inc., as the
sole stockholder of the Company (“Aventis”), passed resolutions appointing Olivier Bogillot and Debora C. Pellicano as the
sole directors of the Company.
Officers
As
of the Effective Time, in accordance with the Merger Agreement, Michael Tolpa, the President and sole officer of Purchaser immediately
prior to the Effective Time became the President and sole officer of the Company as the surviving corporation. After the Effective Time
but before Aventis passed the resolutions described above, Michael Tolpa, as the sole director of the Company, passed resolutions appointing
(or confirming the continued appointment of) the following individuals as officers of the Company: (i) Olivier Bogillot, President, (ii)
Debora Pellicano, Vice President, Chief Financial Officer, (iii) Francisco Leon, Chief Scientific Officer, (iv) Eleanor L. Ramos, Chief
Medical Officer, (v) Jason Hoitt, Chief Commercial Officer, (vi) Benedict Osorio, Chief Quality Officer, (vii) Christina Yi, Chief Operations
Officer, (viii) Jamie Haney, Secretary, (ix) Stacy Apgar, Assistant Secretary and (x) Michael Tolpa, Treasurer.
| Item
5.03 | Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
Pursuant
to the terms of the Merger Agreement, as of the Effective Time, the Company’s second amended and restated certificate of incorporation
was amended and restated in its entirety, and the Company’s amended and restated bylaws were amended and restated in their entirety.
Copies of the third amended and restated certificate of incorporation and second amended and restated bylaws are filed as Exhibits 3.1
and 3.2, respectively, and are incorporated herein by reference.
| Item 9.01 |
Financial Statements and Exhibits. |
(d)
Exhibits.
*Certain
exhibits and the schedules to the Agreement and Plan of Merger have been omitted from this filing pursuant to Item 601(b)(2)(ii) of Regulation
S-K. Pursuant to Item 601(a)(5) of Regulation S-K, the Company hereby agrees to supplementally furnish to the SEC upon request any omitted
schedule or exhibit to the Agreement and Plan of Merger.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Provention
Bio, Inc. |
| |
|
| |
By: |
/s/
Michael Tolpa |
| |
Name: |
Michael
Tolpa |
| |
Title: |
Treasurer |
Dated:
April 27, 2023
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Oct 2024 to Nov 2024
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Nov 2023 to Nov 2024
